Biomarkers for therapy selection in metastatic urothelial cancer

Tomi Jun; Jonathan Anker; Matthew D. Galsky

doi:10.20517/2394-4722.2021.171

Biomarkers for therapy selection in metastatic urothelial cancer

Tomi Jun, Jonathan Anker, Matthew D. Galsky

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

The treatment of metastatic urothelial cancer (mUC) has been transformed by recent progress in clinical trials and drug development. There are now three therapeutic classes with proven benefits in mUC: chemotherapy, immunotherapy, and targeted therapy. The optimal sequence and combination of these classes remain to be defined. Biomarker development is essential to guide treatment selection at each therapeutic juncture. Two biomarkers, programmed death-ligand 1 expression and fibroblast growth factor receptor alterations, have been incorporated into the mUC treatment paradigm thus far. This review discusses predictive biomarkers in development and their potential to influence mUC treatment selection moving forward.

Original language	English
Article number	1
Journal	Journal of Cancer Metastasis and Treatment
Volume	8
DOIs	https://doi.org/10.20517/2394-4722.2021.171
State	Published - 2022

Keywords

Metastatic urothelial cancer
antibody-drug conjugates
biomarkers
chemotherapy
immunotherapy
targeted therapy

Access to Document

10.20517/2394-4722.2021.171

Cite this

@article{a6d01b08b71449e9a2640e747bcec959,

title = "Biomarkers for therapy selection in metastatic urothelial cancer",

abstract = "The treatment of metastatic urothelial cancer (mUC) has been transformed by recent progress in clinical trials and drug development. There are now three therapeutic classes with proven benefits in mUC: chemotherapy, immunotherapy, and targeted therapy. The optimal sequence and combination of these classes remain to be defined. Biomarker development is essential to guide treatment selection at each therapeutic juncture. Two biomarkers, programmed death-ligand 1 expression and fibroblast growth factor receptor alterations, have been incorporated into the mUC treatment paradigm thus far. This review discusses predictive biomarkers in development and their potential to influence mUC treatment selection moving forward.",

keywords = "Metastatic urothelial cancer, antibody-drug conjugates, biomarkers, chemotherapy, immunotherapy, targeted therapy",

author = "Tomi Jun and Jonathan Anker and Galsky, {Matthew D.}",

note = "Funding Information: Tomi Jun is employed by Sema4. Matthew Galsky has received research funding from Bristol Myers Squibb, Novartis, Dendreon, Astra Zeneca, Merck, Genentech; has consultant or advisory board roles for Bristol Myers Squibb, Merck, Genentech, AstraZeneca, Pfizer, EMD Serono, Seattle Genetics, Janssen, Numab, Dragonfly, GlaxoSmithKline, Basilea, UroGen, and Rappta Therapeutics. Publisher Copyright: {\textcopyright} The Author(s) 2022.",

year = "2022",

doi = "10.20517/2394-4722.2021.171",

language = "English",

volume = "8",

journal = "Journal of Cancer Metastasis and Treatment",

issn = "2394-4722",

publisher = "OAE Publishing Inc.",

}

TY - JOUR

T1 - Biomarkers for therapy selection in metastatic urothelial cancer

AU - Jun, Tomi

AU - Anker, Jonathan

AU - Galsky, Matthew D.

N1 - Funding Information: Tomi Jun is employed by Sema4. Matthew Galsky has received research funding from Bristol Myers Squibb, Novartis, Dendreon, Astra Zeneca, Merck, Genentech; has consultant or advisory board roles for Bristol Myers Squibb, Merck, Genentech, AstraZeneca, Pfizer, EMD Serono, Seattle Genetics, Janssen, Numab, Dragonfly, GlaxoSmithKline, Basilea, UroGen, and Rappta Therapeutics. Publisher Copyright: © The Author(s) 2022.

PY - 2022

Y1 - 2022

N2 - The treatment of metastatic urothelial cancer (mUC) has been transformed by recent progress in clinical trials and drug development. There are now three therapeutic classes with proven benefits in mUC: chemotherapy, immunotherapy, and targeted therapy. The optimal sequence and combination of these classes remain to be defined. Biomarker development is essential to guide treatment selection at each therapeutic juncture. Two biomarkers, programmed death-ligand 1 expression and fibroblast growth factor receptor alterations, have been incorporated into the mUC treatment paradigm thus far. This review discusses predictive biomarkers in development and their potential to influence mUC treatment selection moving forward.

AB - The treatment of metastatic urothelial cancer (mUC) has been transformed by recent progress in clinical trials and drug development. There are now three therapeutic classes with proven benefits in mUC: chemotherapy, immunotherapy, and targeted therapy. The optimal sequence and combination of these classes remain to be defined. Biomarker development is essential to guide treatment selection at each therapeutic juncture. Two biomarkers, programmed death-ligand 1 expression and fibroblast growth factor receptor alterations, have been incorporated into the mUC treatment paradigm thus far. This review discusses predictive biomarkers in development and their potential to influence mUC treatment selection moving forward.

KW - Metastatic urothelial cancer

KW - antibody-drug conjugates

KW - biomarkers

KW - chemotherapy

KW - immunotherapy

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85136243654&partnerID=8YFLogxK

U2 - 10.20517/2394-4722.2021.171

DO - 10.20517/2394-4722.2021.171

M3 - Review article

AN - SCOPUS:85136243654

SN - 2394-4722

VL - 8

JO - Journal of Cancer Metastasis and Treatment

JF - Journal of Cancer Metastasis and Treatment

M1 - 1

ER -

Biomarkers for therapy selection in metastatic urothelial cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this